Secondary analysis reveals gut microbiota differences in patients with Parkinson’s disease and/or cognitive impairment

Abstract

Background: Parkinson’s disease (PD) is a neurodegenerative disorder, and the main clinical characteristics are bradykinesia and muscle stiffness. Cognitive impairment (CI) is a prevalent non-motor manifestation observed in individuals with PD. According to disease severity, it can be divided into PD with mild cognitive impairment (MCI) and PD dementia. CI in PD patients may precede motor symptoms, and the gut microbiota plays an important role in PD pathogenesis. Therefore, gut microbiota may be one of the diagnostic targets for PD-CI.

Methods: This study compared the gut microbiota of 43 PD-CI patients [Montreal Cognitive Assessment (MoCA) score < 26] and 38 PD patients without CI (MoCA ≥ 26). Patients’ neuropsychological conditions, depression scale, and brain structure scanned by magnetic resonance imaging (MRI) were also recorded. The fecal metagenomic datasets of patients with PD, PD-CI, and CI only were retrieved from public databases for reanalysis to explore the relationship between PD, CI, and gut microbiota.

Results: We found that the cortical thickness and the volume of the hippocampus, gray matter, and thalamus were significantly reduced among patients with PD-CI compared to PD without CI (P < 0.05). Moreover, the gut microbiome in patients with PD-CI had fewer short-chain fatty acid (SCFA) producing bacteria and more pathogenic bacteria. There were also alterations in patterns of metabolic pathway-encoding genes. Additionally, PD affected gut microbiota more than CI.

Conclusion: CI may aggravate the severity of PD, but it did not drastically alter subjects’ gut microbiota. This study reveals the relationship between gut microbiota, PD, and CI.

Keywords

Parkinson’s disease / cognitive impairment / gut microbiota / hippocampus

References

[1] Bloem BR,Klein C.Parkinson’s disease.Lancet2021;397:2284-303

[2] Boertien JM, Murtomäki K, Pereira PAB, et al; PPNN Study Group. Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease. NPJ Parkinsons Dis 2022;8:129. PMCID:PMC9551094

[3] Lancet. What next in Parkinson’s disease?.Lancet2024;403:219

[4] Chen H,Wang J.Parkinson’s disease research in a prospective cohort in China.Parkinsonism Relat Disord2015;21:1200-4 PMCID:PMC4587359

[5] Leite Silva ABR,Diógenes GP.Premotor, nonmotor and motor symptoms of Parkinson’s disease: a new clinical state of the art.Ageing Res Rev2023;84:101834

[6] Williams-Gray CH,Goris A.The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort.Brain2009;132:2958-69

[7] Williams-Gray CH,Evans JR.The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort.J Neurol Neurosurg Psychiatry2013;84:1258-64

[8] Wallen ZD,Twa G.Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms.Nat Commun2022;13:6958 PMCID:PMC9663292

[9] Ascherio A.The epidemiology of Parkinson’s disease: risk factors and prevention.Lancet Neurol2016;15:1257-72

[10] Romano S,Bedarf JR,Hildebrand F.Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation.NPJ Parkinsons Dis2021;7:27 PMCID:PMC7946946

[11] Boktor JC,Verhagen Metman LA.Integrated multi-cohort analysis of the Parkinson’s disease gut metagenome.Mov Disord2023;38:399-409

[12] Liang X,Cao WT.Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis.Transl Neurodegener2022;11:49 PMCID:PMC9661756

[13] Ren T,Qiu Y.Gut microbiota altered in mild cognitive impairment compared with normal cognition in sporadic Parkinson’s disease.Front Neurol2020;11:137 PMCID:PMC7052381

[14] Bajaj JS,Ridlon JM.Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.Am J Physiol Gastrointest Liver Physiol2012;303:G675-85 PMCID:PMC3468538

[15] Cersosimo MG.Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease.Neurobiol Dis2012;46:559-64

[16] Tan AH,Lang AE.The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.Nat Rev Neurol2022;18:476-95

[17] Boehme M,Bastiaanssen TFS.Microbiota from young mice counteracts selective age-associated behavioral deficits.Nat Aging2021;1:666-76

[18] Sun MF,Zhou ZL.Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.Brain Behav Immun2018;70:48-60

[19] Sun H,Liu Y.Probiotics synergized with conventional regimen in managing Parkinson’s disease.NPJ Parkinsons Dis2022;8:62 PMCID:PMC9130297

[20] Chi H,Sun C.Blood neuroexosomal mitochondrial proteins predict Alzheimer disease in diabetes.Diabetes2022;71:1313-23

[21] Li D,Luo R,Lam TW.MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph.Bioinformatics2015;31:1674-6

[22] Liu A,Xu N.Adjunctive probiotics alleviates asthmatic symptoms via modulating the gut microbiome and serum metabolome.Microbiol Spectr2021;9:e0085921 PMCID:PMC8510161

[23] Caspi R,Keseler IM.The MetaCyc database of metabolic pathways and enzymes - a 2019 update.Nucleic Acids Res2020;48:D445-53 PMCID:PMC6943030

[24] Magnúsdóttir S,Kutt L.Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota.Nat Biotechnol2017;35:81-9

[25] Mallick H,Mclver LJ.Predictive metabolomic profiling of microbial communities using amplicon or metagenomic sequences.Nat Commun2019;10:3136 PMCID:PMC6637180

[26] Hoehn MM.Parkinsonism: onset, progression and mortality.Neurology1967;17:427-42

[27] Sen A,Coskun C,Nacaroglu SA.Effects of levodopa on retina in Parkinson disease.Eur J Ophthalmol2014;24:114-9

[28] Dugger BN.Pathology of neurodegenerative diseases.Cold Spring Harb Perspect Biol2017;9:a028035 PMCID:PMC5495060

[29] Houser MC.The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?.NPJ Parkinsons Dis2017;3:3 PMCID:PMC5445611

[30] Liu J,Ye T.Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson’s disease: a bench-to-bedside translational approach.Brain Behav Immun2024;117:270-82

[31] Qian Y,Xu S.Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease.Brain Behav Immun2018;70:194-202

[32] Aljumaah MR,Roach J,Azcarate Peril MA.The gut microbiome, mild cognitive impairment, and probiotics: a randomized clinical trial in middle-aged and older adults.Clin Nutr2022;41:2565-76

[33] Bonham KS, Fahur Bottino G, McCann SH, et al; RESONANCE Consortium. Gut-resident microorganisms and their genes are associated with cognition and neuroanatomy in children. Sci Adv 2023;9:eadi0497. PMCID:PMC10745691

[34] Li N,Wang Y.Akkermansia muciniphila supplementation prevents cognitive impairment in sleep-deprived mice by modulating microglial engulfment of synapses.Gut Microbes2023;15:2252764 PMCID:PMC10484034

[35] Zheng M,Yang X.Probiotic Clostridium butyricum ameliorates cognitive impairment in obesity via the microbiota-gut-brain axis.Brain Behav Immun2024;115:565-87

[36] Cattaneo A, Cattane N, Galluzzi S, et al; INDIA-FBP Group. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 2017;49:60-8.

[37] Kim N,Ju IG.Transplantation of gut microbiota derived from Alzheimer’s disease mouse model impairs memory function and neurogenesis in C57BL/6 mice.Brain Behav Immun2021;98:357-65

[38] Song L,Zheng H.Roseburia hominis alleviates neuroinflammation via short-chain fatty acids through histone deacetylase inhibition.Mol Nutr Food Res2022;66:e2200164 PMCID:PMC9787297

[39] Chen SJ,Liao HY.Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease.Neurology2022;98:e848-58 PMCID:PMC8883514

[40] Tan AH,Lim SY.Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics.Ann Neurol2021;89:546-59

[41] Nishiwaki H,Hamaguchi T.Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease.NPJ Parkinsons Dis2022;8:65 PMCID:PMC9160257

[42] Liu P,Peng G.Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort.Brain Behav Immun2019;80:633-43